trending Market Intelligence /marketintelligence/en/news-insights/trending/iBghxq5eS_q802y7NOYPyw2 content esgSubNav
In This List

Master Pharm Q1 profit climbs 56.3% YOY

Blog

HDFC Securities Investment Research Now Available through S&P Capital IQ Pro

Podcast

MediaTalk | Season 2
Ep.2 Back to the Box Office

Blog

The Marriage of Two Best-in-Class Solutions Delivers a Significant Advancement in Data Visualization and Technical Analysis

Case Study

A Green Lender Adopts a Robust Approach for Assessing Project Finance Credit Risks


Master Pharm Q1 profit climbs 56.3% YOY

Master Pharm SA said its first-quarter normalized net income came to 1.3 million zlotys, a rise of 56.3% from 800,630 zlotys in the year-earlier period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

The normalized profit margin fell to 10.9% from 11.3% in the year-earlier period.

Total revenue rose 61.0% on an annual basis to 11.5 million zlotys from 7.1 million zlotys, and total operating expenses rose 61.3% on an annual basis to 9.4 million zlotys from 5.9 million zlotys.

Reported net income increased 28.8% year over year to 1.3 million zlotys, or 7 groszy per share, from 1.0 million zlotys.

As of May 16, US$1 was equivalent to 3.85 zlotys.